These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1389 related articles for article (PubMed ID: 16409879)

  • 1. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.
    Pouryamout L; Dams J; Wasem J; Dodel R; Neumann A
    Drugs; 2012 Apr; 72(6):789-802. PubMed ID: 22480339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.
    Weycker D; Taneja C; Edelsberg J; Erder MH; Schmitt FA; Setyawan J; Oster G
    Curr Med Res Opin; 2007 May; 23(5):1187-97. PubMed ID: 17519086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Green C; Picot J; Loveman E; Takeda A; Kirby J; Clegg A
    Pharmacoeconomics; 2005; 23(12):1271-82. PubMed ID: 16336020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescribing of drugs for Alzheimer's disease: a South African database analysis.
    Truter I
    Int Psychogeriatr; 2010 Mar; 22(2):264-9. PubMed ID: 20067653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
    Connock M; Burls A; Frew E; Fry-Smith A; Juarez-Garcia A; McCabe C; Wailoo A; Abrams K; Cooper N; Sutton A; O'Hagan A; Moore D
    Health Technol Assess; 2006 Jul; 10(24):iii-iv, ix-136. PubMed ID: 16796930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.
    Connock M; Juarez-Garcia A; Frew E; Mans A; Dretzke J; Fry-Smith A; Moore D
    Health Technol Assess; 2006 Jun; 10(20):iii-iv, ix-113. PubMed ID: 16729919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.
    Hartz S; Getsios D; Tao S; Blume S; Maclaine G
    BMC Neurol; 2012 Feb; 12():2. PubMed ID: 22316501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinesterase inhibitors for Alzheimer's disease.
    Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.
    Hyde C; Peters J; Bond M; Rogers G; Hoyle M; Anderson R; Jeffreys M; Davis S; Thokala P; Moxham T
    Age Ageing; 2013 Jan; 42(1):14-20. PubMed ID: 23179169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
    Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.
    Green C; Dinnes J; Takeda A; Shepherd J; Hartwell D; Cave C; Payne E; Cuthbertson BH
    Health Technol Assess; 2005 Mar; 9(11):1-126, iii-iv. PubMed ID: 15774234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.